Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.
| Revenue (Most Recent Fiscal Year) | $330.53M |
| Net Income (Most Recent Fiscal Year) | $-422.77M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.88 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -35.90% |
| Return on Assets (Trailing 12 Months) | -32.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.56 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.53 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.78 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.57 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.67 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 145.28M |
| Free Float | 127.12M |
| Market Capitalization | $2.11B |
| Average Volume (Last 20 Days) | 1.51M |
| Beta (Past 60 Months) | 1.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |